[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-349698-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-349698-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","conversion-surgery-vs-standard-of-care-in-pancreatic-cancer-oligometastatic-to-the-liver-sonar-randomized-controlled-trial","Conversion surgery vs. standard of care in pancreatic cancer oligometastatic to the liver (SONAR) - randomized controlled trial","","Pancreatic cancer oligometastatic to the liver is an advanced subset defined by a limited number of liver metastases within a single site, yet patients often face poor outcomes. First-line chemotherapy is standard, but the best post-response or stability strategy is uncertain. The SONAR phase-2 multicentric randomized trial compares surgical resection with observation or continuation of chemotherapy in resectable patients after first-line treatment, assessing efficacy and safety.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/conversion-surgery-vs-standard-of-care-in-pancreatic-cancer-oligometastatic-to-the-liver-sonar-randomized-controlled-trial/349698/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/conversion-surgery-vs-standard-of-care-in-pancreatic-cancer-oligometastatic-to-the-liver-sonar-randomized-controlled-trial/349698.png","ImageObject",300,407,{"name":42,"@type":43},"Himbo","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-01","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",14,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What does the SONAR trial compare for resectable oligometastatic pancreatic cancer to the liver?","Question",{"text":63,"@type":64},"It compares conversion surgery versus observation or continuation of chemotherapy for patients with stable disease or response after first-line chemotherapy.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Who is eligible to participate in the trial?",{"text":68,"@type":64},"Patients with pancreatic cancer and up to 3 liver metastases, without extrahepatic disease, who received systemic chemotherapy first and then show disease response or stability are eligible.",{"name":70,"@type":61,"acceptedAnswer":71},"What outcomes will be measured in the SONAR trial?",{"text":72,"@type":64},"Overall survival at two years is the primary outcome, with secondary outcomes including progression-free survival, treatment-related adverse events, quality of life, and translational analyses.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},349698,1790307832,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":124,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},687197100911,"https://ap-avatar.wpscdn.com/avatar/a000239b6f1da00475?x-image-process=image/resize,m_fixed,w_180,h_180&k=1785132997149421697","Guastella et al. BMC Cancer (2026) 26:44 BMC Cancer  \n[https://doi.org/10.1186/s12885-025-15183-9](https://doi.org/10.1186/s12885-025-15183-9)  \nSTUDY PROTOCOL Open Access  \nConversion surgery vs. standard of care  in pancreaTic cancer oligometastatic to the  \nliver (SONAR: Surgery in Oligometastatic paNcreatic cAnceR) a randomized controlled trial  \nRiccardo Guastella1,2, Giampaolo Perri1,2, Domenico Bassi1,2, Nicola Canitano1,2, Virginia Padoan 1,2, Samuele Grandi1,2, Riccardo Pellegrini1,2, Letizia Procaccio3, Francesca Bergamo3, Sara Lonardi3, Riccardo Carandina4, Enrico Gringeri1,2, Giovanni Marchegiani1,2* and Umberto Cillo1,2  \nAbstract  \nBackground Pancreatic cancer oligometastatic to the liver represents a distinct subset of advanced disease, presenting a limited number of metastases in a single site. First-line chemotherapy is considered the standard of care, with a poor overall prognosis. However, the optimal strategy for oligometastatic patients presenting response or stability after treatment is unclear. In selected patients, surgical resection is associated with prolonged survival, according to retrospective series. The aim of this randomized clinical trial is to compare the efficacy and safety of surgery versus observation or continuation of chemotherapy in patients with resectable pancreatic cancer oligometastatic to the liver with stable disease or response after first-line chemotherapy.  \nMethods The study is a phase-2 multicentric randomized controlled trial with 1:1 allocation ratio. Patients diagnosed with pancreatic cancer and a limited number (up to 3) of liver metastases, with no evidence of extrahepatic disease, who received systemic chemotherapy as the initial treatment and with disease response or stability after therapy will be considered eligible patients. Patients will be randomized to either Arm A (surgery) or Arm B (observation or continuation of chemotherapy) . The primary outcome will be overall survival at two years, with secondary outcomes including progression-free survival, treatment-related adverse events, quality of life and translational analyses. Discussion This randomized controlled trial will evaluate the role of surgery in pancreatic cancer oligometastatic to the liver after response or stability to first-line chemotherapy. While systemic therapy remains the standard of care, selected patients may benefit from surgical resection. By comparing surgery to observation or continuation of chemotherapy, the SONAR trial aims to fill a critical gap in treatment strategies and potentially refine the management of this challenging disease.  \n*Correspondence:  \nGiovanni Marchegiani [giovanni. marchegiani@unipd.it](giovanni. marchegiani@unipd.it)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/.)[.](http://creativecommons.org/licenses/by/4.0/.)  \nGuastella et al. BMC Cancer (2026) 26:44 Page 2 of 10  \nTrial registration The trial has been registered [at ClinicalTrials.gov](at ClinicalTrials.gov) on 15/11/2024 before inclusion of the first patient (NCT06690528) .  \nKeyw","cbCaig5N9Gk7fdzg","https://ap.wps.com/l/cbCaig5N9Gk7fdzg","pdf",2037099,"English","# Background\n# Methods\n# Discussion\n# Trial registration\n# Keywords","[{\"question\":\"What does the SONAR trial compare for resectable oligometastatic pancreatic cancer to the liver?\",\"answer\":\"It compares conversion surgery versus observation or continuation of chemotherapy for patients with stable disease or response after first-line chemotherapy.\"},{\"question\":\"Who is eligible to participate in the trial?\",\"answer\":\"Patients with pancreatic cancer and up to 3 liver metastases, without extrahepatic disease, who received systemic chemotherapy first and then show disease response or stability are eligible.\"},{\"question\":\"What outcomes will be measured in the SONAR trial?\",\"answer\":\"Overall survival at two years is the primary outcome, with secondary outcomes including progression-free survival, treatment-related adverse events, quality of life, and translational analyses.\"}]","Conversion surgery vs. standard of care in pancreatic cancer oligometastatic to the liver (SONAR) - randomized controlled trial | PDF",1790085113,25,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e04e0c88d296e3ac77ae557402855008.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f2d0ddbc934d88a835af9222a1f2ed12.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5f73e7f9a264e2a4daca5a2caab51b4c.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d7cfa33f6efd4a7ce5a3515f128cff9c.webp",980,1306]